23-24 April 2009, Brussels, Belgium.
There is clearly an increasing need for more innovative pricing and reimbursement agreements to help to balance the (often) conflicting objectives of pharmaceutical and medical technology manufacturers, payers, health technology assessors (HTA), physicians and patients.

There is a sustained increase in the cost of healthcare and ever-increasing range of expensive drugs and technologies available as potential therapies. Clearly, difficult choices need to be made by HTAs about which products receive funding from increasingly restricted healthcare budgets, especially with often insufficient clinical and real-life evidence available.

In terms of innovative agreements, risk-sharing and value-based schemes (for example) are being proposed more often by more manufacturers, in more countries. Such agreements are increasingly being seen as a method in which pharma and medical device companies can obtain HTA approval to finance the drug from limited budgets, but also a strategy to gain a competitive advantage and preferential market access.

Both life sciences companies and policy-makers are looking to achieve a clearer picture of how risk-sharing and value-based agreements can and do work effectively in the real-world. Many complex agreements exist in various countries, whilst some governments and pharma companies in other markets may alternatively have less experience with such schemes.

Many stakeholders need answers to important questions such as: "What is the definition of risk-sharing and value-based pricing schemes? Are such schemes necessary? What are the alternatives? What successful models exist? How can clear endpoints and goals be defined? How can we measure performance effectively? And how different schemes are being viewed by different stakeholders? Can risk-sharing and value-based agreements bring a competitive advantage to pharma companies?"

Why Attend?

  • Benchmark, network and co-operate with policy makers and key, influential figures. Get the best and most focused picture of risk-sharing and value-based pricing models today.
  • Understand what are the most up to date, innovative agreement solutions and future trends in different countries globally.
  • Find out if risk-sharing and value-based pricing schemes can help pharma and medical device manufacturers achieve preferential market access and a competitive advantage.
  • Learn how drug effectiveness, value and safety is being demonstrated in different regions, in real-life.
  • Understand the best ways to communicate value with stakeholders and achieve maximum patient and market access.
  • Hear the perspectives of all stakeholder groups: Ministries of Health, HTA Agencies, Insurers, Doctors, Patients and patient groups, Health economists and the Pharmaceutical Industry.
  • Discover how payers are evaluating a range of complex pricing and reimbursement agreements.
  • Understand what patients want and what they define as a quality treatment, that enhances their lives.

Who Should Attend?
Pharmaceutical companies, Vice-Presidents, Directors, Managers involved in:
Pricing & Reimbursement, Health Economics & Outcomes, Government & Stakeholder Relations, Regulatory Affairs, Medical Affairs, Marketing, Therapy Area Heads, Market Access, Country Managers

Solution providers consultants:
CEOs, Business Development, Senior Consultants, Regional Heads

Independent Academics, Health Economists, Senior Doctors, & Patient Representatives.

For further information and registration, please visit:

About NextLevel Pharma
NextLevel Pharma is a leading, global strategic business information and opportunity provider for the international life sciences industry.

NextLevel Pharma brings the life sciences industry closer together and organise intelligent conferences and events for industry, personalised meetings for individual companies, as well as tailored partnering services.

For more information, please visit www.nextlevelpharma.com.